Search SRTA
Strata Critical Medical, Inc.
Nasdaq · CIK 1779128
Last close4.73
Daily change-0.10 (-2.07%)
10 Years gain-51.49%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SRTA · STANDARD
SIC 8000 · Services-Health Services · Fiscal year end 1231
Fundamental
70.5Momentum
80.1Acceleration
82.8Confidence
83.0Annual Revenue7
Quarterly Revenue23
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.0 / 25
Quality21.1 / 25
Capital Efficiency10.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics1.9 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.1279 percentage points.
Operating leverageOperating margin improved by 6.0169 percentage points.
ROIC expansionROIC improved by 7.3662 percentage points.
Warnings
Heavy share dilution · HIGHDiluted share count increased 7.9133%.
Key Metrics
Revenue Growth TTM78.51%OK
Revenue CAGR 3Y10.5%OK
Gross Margin21.32%OK
Operating Margin-7.96%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-8.27%OK
Incremental Operating Margin 3Y48.93%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y7.91%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $197.14M | $41.13M | -$22.35M | -$48.91M | -$58.51M | 20.86% | -11.34% | -29.68% | -11.3% | 82.09M |
| 2025 FY Dec 31, 2024 | $146.82M | $29.59M | -$22.53M | -$2.52M | -$33.38M | 20.15% | -15.34% | -22.74% | -21.84% | 77.5M |
| 2024 FY Dec 31, 2023 | $225.18M | $42.12M | -$68.12M | -$32.35M | -$34.46M | 18.71% | -30.25% | -15.3% | -71.48% | 73.52M |
| 2023 FY Dec 31, 2022 | $146.12M | $22.28M | -$53.53M | -$37.13M | -$37.86M | 15.24% | -36.63% | -25.91% | -121.67% | 71.24M |
| 2022 FY Sep 30, 2021 | $50.53M | $10.52M | -$24.09M | -$15.62M | -$15.91M | 20.82% | -47.68% | -31.49% | n/a | 42.88M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $234.30M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-052256, 0001628280-25-050870 |
| Revenue Growth TTM | 78.51% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-052256, 0001628280-25-050870 |
| Revenue CAGR 3Y | 10.5% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-013628 |
| Revenue CAGR 5Y | 53.1% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-013628 |
| Gross Profit CAGR 3Y | 22.68% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-013628 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-052256, 0001628280-25-050870 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 21.32% | Gross Profit / Revenue | OK | 0001628280-26-052256, 0001628280-25-050870 |
| Operating Margin | -7.96% | Operating Income / Revenue | OK | 0001628280-26-052256, 0001628280-25-050870 |
| ROIC | -8.27% | NOPAT / Average Invested Capital | OK | 0001628280-26-052256, 0001628280-25-050870 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-052256 |
| Current Ratio | 2.64x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.72 | Revenue / Diluted Shares | OK | 0001628280-26-052256, 0001628280-25-050870 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |